Intraperitoneal Vascular Endothelial Growth Factor: A Prognostic Factor and the Potential for Intraperitoneal Bevacizumab Use in Peritoneal Surface Malignancies.

Abstract

INTRODUCTION:

Intraperitoneal (IP) vascular endothelial growth factor (VEGF) levels have been shown to vary in the peritoneal cavity of patients with peritoneal surface malignancies. Our purpose was to correlate levels of IP VEGF with overall and disease-free survival to identify whether IP VEGF can be used to prognosticate patients and the possible role of IP bevacizumab.

METHODS:

From February to October 2012, 97 consecutive patients with peritoneal carcinomatosis were treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Intravenous (IV) VEGF levels were taken before surgery, whereas IP VEGF levels were taken at various time points during and after surgery.

RESULTS:

Median follow-up was 19.48 months. On univariate analysis, a lower IP VEGF taken just after incision (T1) was associated with improved overall (P = 0.0004) and disease-free survival (P = 0.0006) at 2 years. A lower T1/IV VEGF ratio also was associated with improved overall (P = 0.004) and disease-free survival (P = 0.0051). On multivariate analysis, a lower T1 was associated with improved overall survival, whereas a lower T1/IV VEGF was associated with improved disease-free survival. On subset analysis, these two variables were associated with improved survival in colorectal cancers.

CONCLUSIONS:

A lower IP VEGF level prior to surgery is associated with improved survival. The use of preoperative intraperitoneal bevacizumab for patients with a heavy disease load should be considered, especially in colorectal cancers.

• Authors: Claramae Shulyn Chia, Olivier Glehen, Naoual Bakrin, Evelyne Decullier, Benoit You, François Noël Gilly, Guillaume Passot
• Journal: Annals of surgical oncology (Ann Surg Oncol) Vol. 22 Suppl 3 Pg. S880-7 (Dec 2015) ISSN: 1534-4681 [Electronic] United States
• PMID: 26040606 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Biomarkers, Tumor
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• Bevacizumab

Topics

• Adult
• Aged
• Angiogenesis Inhibitors (therapeutic use)
• Ascitic Fluid (metabolism)
• Bevacizumab (therapeutic use)
• Biomarkers, Tumor (blood)
• Female
• Follow-Up Studies
• Humans
• Injections, Intraperitoneal
• Male
• Middle Aged
• Neoplasm Staging
• Neoplasms (blood, drug therapy, pathology)
• Peritoneal Neoplasms (blood, drug therapy, secondary)
• Prognosis
• Survival Rate
• Vascular Endothelial Growth Factor A (blood)